| Ronald Goldberg, MD | |
|
275 Sandwich St, Plymouth, MA 02360-2183 | |
| (508) 830-2120 | |
| Not Available |
| Full Name | Ronald Goldberg |
|---|---|
| Gender | Male |
| Speciality | Radiology - Diagnostic Radiology |
| Location | 275 Sandwich St, Plymouth, Massachusetts |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1669452769 | NPI | - | NPPES |
| 2065479 | Medicaid | MA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2085R0202X | Radiology - Diagnostic Radiology | 36325 (Massachusetts) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Ronald Goldberg, MD Po Box 9132, Brookline, MA 02446-9132 Ph: (800) 927-0002 | Ronald Goldberg, MD 275 Sandwich St, Plymouth, MA 02360-2183 Ph: (508) 830-2120 |
News Archive
Neogen Corporation has announced the development of a breakthrough pathogen detection and identification technology that provides next day, DNA-specific test results for seven pathogenic E. coli strains. The technology could be adapted to target almost any bacterium of concern in almost any food sample type.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues finds that, following its launch and uptake, GlaxoSmithKline's angiogenesis inhibitor Votrient (formerly Armala) will garner sales of $640 million by 2018 and will take significant market share away from Pfizer's Sutent. In 2008, Sutent had accounted for 61 percent of sales in the angiogenesis inhibitor drug class.
Only about 1% of newly developed drugs are for tropical diseases, such as African sleeping sickness and dengue fever. While patent incentives have driven commercial pharmaceutical companies to make Western health care the envy of the world, the commercial model only works if companies can sell enough patented products to cover their R&D costs and produce profits for shareholders.
Depression is the strongest predictor of death in the first decade following a diagnosis of coronary heart disease, according to a new study by researchers at the Intermountain Medical Center Heart Institute in Salt Lake City.
NormOxys, Inc., a biotechnology company developing a novel class of small molecule drugs which enhance the body's ability to deliver oxygen to diseased tissues, today announced that it has raised $17.5 million in a Series B financing round. The financing was led by a new investor, Care Capital, LLC, with participation from existing venture investor Index Ventures.
› Verified 8 days ago
Justino Fernandes, MD Radiology Medicare: Not Enrolled in Medicare Practice Location: 275 Sandwich St, Plymouth, MA 02360 Phone: 508-830-2120 | |
Eugene Kang, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 275 Sandwich St, Plymouth, MA 02360 Phone: 508-830-2120 | |
Gordon K Kanzer, M.D. Radiology Medicare: Not Enrolled in Medicare Practice Location: 3 Cedarhill Park Dr, Plymouth, MA 02360 Phone: 508-888-2270 | |
James Galvin, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 275 Sandwich St, Plymouth, MA 02360 Phone: 508-830-2120 | |
Dr. Colleen W Fine, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 275 Sandwich St, Plymouth, MA 02360 Phone: 508-830-2121 | |
David Betteridge, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 275 Sandwich St, Plymouth, MA 02360 Phone: 508-830-2120 |